Thoracic Surgery in Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Mutant After Tyrosine Kinase Inhibitor Therapy

被引：0
|
作者：
Hsiao, C. [1 ]
Kuo, S. [2 ,3 ]
Chen, K. [4 ]
Chen, J. [2 ,3 ]
机构：
[1] Cheng Hsin Gen Hosp, Surg, Taipei, Taiwan
[2] Natl Taiwan Univ Hosp, Surg, Taipei, Taiwan
[3] Natl Taiwan Univ, Coll Med, Taipei, Taiwan
[4] Natl Taiwan Univ, Dept Surg, Taipei, Taiwan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
Tyrosine kinase inhibitors; Thoracic Surgery; non-small cell lung cancer;
D O I：
10.1016/j.jtho.2018.08.592
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.01-36
引用
收藏
页码：S474 / S474
页数：1
相关论文
共 50 条
  • [41] Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
    Sequist, Lecia V.
    ONCOLOGIST, 2007, 12 (03): : 325 - 330
  • [42] Cluster analysis of deterioration sites after first-line epidermal growth factor receptor-tyrosine kinase inhibitor in epidermal growth factor receptor mutated non-small cell lung cancer
    Okauchi, Shinichiro
    Miyazaki, Kunihiko
    Satoh, Hiroaki
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2022, 26 (02): : 123 - 127
  • [43] Tumor immune microenvironment in epidermal growth factor receptor-mutated non-small cell lung cancer before and after epidermal growth factor receptor tyrosine kinase inhibitor treatment: a narrative review
    Liu, Lihui
    Wang, Chao
    Li, Sini
    Bai, Hua
    Wang, Jie
    TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (09) : 3823 - 3839
  • [44] Epidermal growth factor receptor tyrosine kinase inhibitors with conventional chemotherapy for the treatment of non-small cell lung cancer
    Gao, Yuan
    Song, PingPing
    Li, Hui
    Guo, HongBo
    Jia, Hui
    Zhang, BaiJiang
    ONCOTARGETS AND THERAPY, 2016, 9 : 13 - 20
  • [45] Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
    Engelman, Jeffrey A.
    Jaenne, Pasi A.
    CLINICAL CANCER RESEARCH, 2008, 14 (10) : 2895 - 2899
  • [46] 'Targeting' the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa®) in non-small cell lung cancer (NSCLC)
    Pao, W
    Miller, VA
    Kris, MG
    SEMINARS IN CANCER BIOLOGY, 2004, 14 (01) : 33 - 40
  • [47] Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
    Riely, Gregory J.
    JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (06) : S146 - S149
  • [48] Effects of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in EGFR-mutated non-small cell lung cancer
    Yang, Guangdie
    Yao, Yinan
    Zhou, Jianya
    Zhao, Qiong
    ONCOLOGY REPORTS, 2012, 27 (06) : 2066 - 2072
  • [49] Clinical approaches to treat patients with non-small cell lung cancer and epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance
    Tartarone, Alfredo
    Lerose, Rosa
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2015, 9 (05) : 242 - 250
  • [50] Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer - A randomized trial
    Kris, MG
    Natale, RB
    Herbst, RS
    Lynch, TJ
    Prager, D
    Belani, CP
    Schiller, JH
    Kelly, K
    Spiridonidis, H
    Sandler, A
    Albain, KS
    Cella, D
    Wolf, MK
    Averbuch, SD
    Ochs, JJ
    Kay, AC
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (16): : 2149 - 2158
12345